Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Light-Based scan could spot prostate cancer faster

NCT ID NCT02394223

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new imaging technique called Full Field Optical Coherence Tomography (FFOCT) to see if it can detect prostate cancer in biopsy samples as well as standard microscope analysis. Researchers compared FFOCT results to the usual pathology exam in 91 men with elevated PSA levels. The goal was to see if FFOCT could provide a quicker or more detailed diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Full Field Optical Coherence Tomography (FFOCT) imaging procedure
What this could lead to
If successful, FFOCT could provide a faster, more accurate way to diagnose prostate cancer from biopsy samples.
What could go wrong
This is a small, completed study with 91 participants, and the technique is still experimental. It may not prove better than standard methods in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

91 people

The number who actually took part.

Started

Jan 2016

Finished

Jan 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged 45 to 75 years old, with PSA level 4.0 ng/mL

Ages

45 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Patient aged 45 to 75 years old included * \- PSA level 4.0 ng/mL * \- Patient referred for trans rectal ultrasound-guided prostate biopsy with additional MRI-targeted biopsies * \- Patient no opposed to participate in the study * Patient affiliated to the French National Social Security System Exclusion Criteria: * Known prostate cancer * Patients unable to understand the course of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Patients with PSA level 4.0 NG/ML are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Patients with PSA level 4.0 NG/ML

Contacts and locations

Locations

  • Assistance Publique - Hôpitaux de Paris Cochin Hospital

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.